Febrile neutropenia was reported in 4% of patients receiving TAS-102 compared with no patients receiving placebo; 9% of patients who developed neutropenia received granulocyte colony-stimulating factor, with one treatment-related death resulting from septic shock. The gene discussed is CSF3; the disease is neutropenia.